The first study reveals the effectiveness of the third dose of the Pfizer vaccine


The two companies said the study, involving more than 10,000 participants over 16 years of age, is the first trial to look at booster doses and their efficacy.

و .شارت Pfizer-Biontech The study was conducted at a time when the delta mutated was the prevailing fluidity in the world United State.

The participants in the study received the booster doses about 11 months after they received the second dose of the vaccine, and after taking it, five people were infected with the Corona virus, which means that the effectiveness rate of the third dose in preventing the virus increased by more than 95 percent.

Pfizer CEO Albert Borla said: “These findings provide further evidence of the benefits of reinforcers in an effort to protect people well from disease.”

Burla added: “In addition to our efforts to increase global access and uptake among non-vaccinators, we believe boosters play a critical role in addressing the ongoing public health threat due to these the pandemic“.

The US Food and Drug Administration has approved the administration of booster doses of Pfizer-Biontech Vaccines and Moderna and Johnson & Johnson, for people 65 years of age and older who are at high risk of infection from the virus.


Please enter your comment!
Please enter your name here